An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
Clinical trial NCT03843892 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT03843892
- Sponsor
- Boehringer Ingelheim
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.